DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Clinical trials for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New 'Living Drug' trial seeks to fight tough blood cancers
Disease control Recruiting nowThis is an early-stage study to find a safe dose and check the initial safety of a new CAR-T cell therapy called GF-CART01. It is for adults aged 18-70 with certain advanced B-cell blood cancers that have come back or not responded to at least two prior treatments. The therapy in…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 20:11 UTC
-
New pill tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of an oral drug called VK-2019 for adults with a specific type of aggressive lymphoma linked to the Epstein-Barr virus (EBV). The lymphoma must have returned or not responded to at least two prior treatments. Participants…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New Two-Pronged cancer therapy aims to outsmart relapsed lymphoma
Disease control Recruiting nowThis study is testing a new, experimental CAR T-cell therapy called ronde-cel against currently approved CAR T-cell therapies for patients with aggressive large B-cell lymphoma that has returned or not responded to initial chemotherapy. The new therapy is designed to target two m…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for patients where CAR-T falls short
Disease control Recruiting nowThis early-stage study is testing a new two-drug combination for patients with B-cell lymphoma. It is for people whose cancer did not respond well enough to a powerful treatment called CAR-T therapy. The goal is to see if adding an oral drug (CC-99282) to an existing antibody dru…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: Nathan Denlinger • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC